| 股票简称：新化股份 | 股票代码：603867 | 公告编号：2025-025 | | --- | --- | --- | | 转债简称：新化转债 | 转债代码：113663 | | 赵建标，男，1969年10月出生，曾任新安江化肥厂、新化有限车间维修工、 设备科科员、异丙胺分厂副厂长、厂长、市场营销部经理、新化股份监事，江苏 新化总经理、新化股份董事、副总经理。现任江苏新化董事长，江苏馨瑞董事长， 公司监事。 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担个别及连带责任。 根据《中华人民共和国公司法》（以下简称《公司法》）及《公司章程》等 规定，浙江新化化工股份有限公司（以下简称"公司"）于 2025 年 5 月 20 日 召开第六届董事会第十七次会议，审议通过了《关于聘任公司副总经理的议案》， 同意聘任赵建标先生（简历详见附件）为公司副总经理，自董事会审议通过之日 起生效，任期同公司第六届董事会任期一致。 董事会提名委员会对赵建标先生的个人履历等资料进行了审核，认为其具备 履行副总经理职责相适应的任职条件，能够胜任所在岗位的要求 ...

浙江新化化工股份有限公司 | 证券简称：新化股份 | 证券代码：603867 | 公告编号：2025-027 | | --- | --- | --- | | 转债简称：新化转债 | 转债代码：113663 | | 关于子公司关联交易的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 1、因建德市伽玛管理咨询合伙企业（有限合伙）份额拟变更，公司拟将全资 子公司浙江新伽玛化学有限公司所持有的预留的建德市伽玛管理咨询合伙企业（有 限合伙）（以下简称伽玛咨询公司）中的24.5%股份按 2024 年净资产份额转让给 其他及新增合伙人，其中 17% 的股份份额转让给应思斌先生，拟转让价格合计为 2,759,429.88 元。应思斌先生系公司董事长，本次交易构成关联交易。 2、本次交易未构成重大资产重组。 3、本次交易已经公司董事会独立董事专门会议2025年第二次会议、第六届 董事会第十七次会议审议通过。本次交易无需提交公司股东大会审议。 4、过去 12 个月内，除本次交易外，公司未与应思斌先生发生关联交易。 一、关联交 ...

| 股票简称：新化股份 | 股票代码：603867 | 公告编号：2025-024 | | --- | --- | --- | | 转债简称：新化转债 | 转债代码：113663 | | 二、职工董事选举情况 浙江新化化工股份有限公司 关于董事辞职及选举职工董事、补选专门委员 会委员的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈 述或者重大遗漏，并对其内容的真实性、准确性和完整性承担个别及连带责任。 一、董事辞职情况 浙江新化化工股份有限公司董事会于近日收到公司非独立董事王勇先生提交 的书面辞职报告。因个人原因，王勇先生申请辞去公司第六届董事会非独立董事 及委员会相关职务，辞职后继续担任公司研究院院长。 根据《公司法》及《公司章程》规定，王勇先生的辞职报告自送达董事会之 日起生效。公司董事会对王勇先生在任职期间勤勉尽责的工作及为公司发展做出 的贡献表示衷心感谢！ 方军伟，男，1970年6月出生，中国国籍，无境外永久居留权，专科学历。 历任新化有限合成氨车间操作工，新化有限化工车间副主任，杭州新成化学有 限公司经理，江西新信公司总经理、法定代表人、执行董事，新化股份监事。 根据《公司法 ...

| 证券代码：603867 | 证券简称：新化股份 | 公告编号：2025-023 | | --- | --- | --- | | 转债简称：新化转债 | 转债代码：113663 | | 浙江新化化工股份有限公司 2024年年度股东会决议公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 本次会议是否有否决议案：无 一、 会议召开和出席情况 (一)股东会召开的时间：2025 年 5 月 20 日 (二)股东会召开的地点：建德市洋溪街道新安江路 909 号（公司会议室） (三)出席会议的普通股股东和恢复表决权的优先股股东及其持有股份情况： | 1、出席会议的股东和代理人人数 | 58 | | --- | --- | | 2、出席会议的股东所持有表决权的股份总数（股） | 58,979,576 | | 3、出席会议的股东所持有表决权股份数占公司有表决权股 | | | 份总数的比例（%） | 30.9857 | (四)表决方式是否符合《公司法》及《公司章程》的规定，股东会主持情况等。 本次股东大会由公司董事会召集， ...

| 证券代码：603867 | 证券简称：新化股份 公告编号：2025-026 | | --- | --- | | 转债代码：113663 | 转债简称：新化转债 | 浙江新化化工股份有限公司 第六届董事会第十七次会议决议公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 一、董事会会议召开情况 浙江新化化工股份有限公司（以下简称"公司"）第六届董事会第十七次会 议（以下简称"本次会议"）于 2025 年 5 月 20 日以现场结合通讯会议方式召开。 本次会议应参会董事 9 名，实际参会董事 8 名，职工董事方军伟先生因公务未能 出席本次会议，会议由董事长应思斌先生主持，本次会议的召开符合《中华人民 共和国公司法》和《公司章程》的规定。 二、董事会会议审议情况 1、审议通过《关于聘任公司副总经理的议案》 具体内容详见公司同日在上海证券交易所网站（http://www.sse.com.cn） 披露的相关公告。 表决结果：同意 8 票，反对 0 票，弃权 0 票。 经公司总经理提名，董事会提名委员会审核通过，董事会聘任赵建标先生为 公司副总经理，任期与本届董事会任期一致。 具体内容详见公司同 ...

新化股份公告，公司于2025年5月20日召开第六届董事会第十七次会议，审议通过了《关于聘任公司副 总经理的议案》，同意聘任赵建标先生为公司副总经理，自董事会审议通过之日起生效，任期同公司第 六届董事会任期一致。赵建标先生，1969年10月出生，曾任新安江化肥厂、新化有限车间维修工、设备 科科员、异丙胺分厂副厂长、厂长、市场营销部经理、新化股份监事，江苏新化总经理、新化股份董 事、副总经理。现任江苏新化董事长，江苏馨瑞董事长，公司监事。截至本公告披露日，赵建标先生直 接持有公司174.34万股股票。 ...

| 股票简称：新化股份 | 股票代码：603867 | 公告编号：2025-022 | | --- | --- | --- | | 转债简称：新化转债 | 转债代码：113663 | | 浙江新化化工股份有限公司 关于2024年年度报告的更正公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担个别及连带责任。 浙江新化化工股份有限公司于2025年4月29日在上海证券交易所网站（www.ss e.com.cn）披露了2024年年度报告，因工作人员疏忽，漏写了前十名转债持有人 情况，现更正如下： 除上述更正外，报告无其他修改。更正内容后的公司《2024 年年度报告》将 与本公告同日重新发布于上海证券交易所网站（www.sse.com.cn）进行披露。公 司对因上述更正给投资者及报告使用人造成的不便深表歉意。今后公司将进一步 强化信息披露编制及审核工作，提高信息披露质量，并欢迎广大投资者持续监督。 特此公告。 浙江新化化工股份有限公司董事会 2025年5月15日 原公告"第九节 债券相关情况-二、可转换公司债券情况-（二）报告期转债 持有人及 ...

Financial Performance - The company achieved operating revenue of CNY 2,965,728,632.94 in 2024, a 14.22% increase compared to 2023[23]. - Net profit attributable to shareholders decreased by 10.18% to CNY 226,913,902.54 in 2024[23]. - The company reported a net profit of CNY 220,842,591.08 after deducting non-recurring gains and losses, down 8.06% from the previous year[23]. - The total assets increased by 9.51% to CNY 4,348,257,272.55 at the end of 2024 compared to the end of 2023[23]. - The company’s cash flow from operating activities was CNY 311,275,444.21, reflecting a 10.61% increase from the previous year[23]. - The company’s net assets attributable to shareholders increased by 5.55% to CNY 2,327,380,949.06 at the end of 2024 compared to the end of 2023[23]. - The operating cost increased by 17.93% to CNY 2,350,008.40 million, primarily due to increased sales of fatty amines and synthetic fragrance products[54]. - The company's R&D expenses rose by 14.84% to CNY 104,471.98 million, reflecting ongoing investment in new technologies and product development[54]. Dividend Distribution - The company plans to distribute a cash dividend of CNY 0.45 per share (including tax), totaling approximately CNY 85.67 million based on a total share capital of 190,379,389 shares after accounting for repurchased shares[6]. - The total cash dividend amount for the latest fiscal year is RMB 85,670,725.05, which represents 37.75% of the net profit attributable to ordinary shareholders[165]. - The cumulative cash dividend amount over the last three fiscal years is RMB 270,183,544.45, with a cash dividend ratio of 100.17% based on the average annual net profit[167]. - For the 2023 fiscal year, the proposed cash dividend is RMB 4.5 per 10 shares, subject to approval at the 2023 annual general meeting and expected to be implemented on June 18, 2024[163]. Audit and Compliance - The company has received a standard unqualified audit report from Tianjian Accounting Firm, ensuring the authenticity and completeness of the financial report[5]. - The company has established a comprehensive internal control system to ensure compliance and risk management, with no significant deficiencies reported during the period[169]. - The internal control audit for 2024 was conducted by Tianjian Accounting Firm, resulting in a standard unqualified opinion[170]. - The company has not reported any significant differences in governance practices compared to regulations set by the China Securities Regulatory Commission[131]. Research and Development - The company applied for 18 national patents in 2024, including 7 invention patents and 11 utility model patents[32]. - The company has established a provincial-level high-tech research and development center and a provincial key laboratory, enhancing its R&D capabilities[96]. - The company employs 173 R&D personnel, making up 14.15% of the total workforce, with 10 holding doctoral degrees[69]. - The company plans to increase its research and development investment to support innovation in product offerings and sustainability initiatives[82]. Environmental Compliance - The company reported a continuous emission of CODCr at 246 mg/L, ammonia nitrogen at 7.74 mg/L, total nitrogen at 20.45 mg/L, and total phosphorus at 0.23 mg/L, which are above the standards set by GB8978-1996[175]. - The company is currently not compliant with the emission standards for sulfur dioxide, nitrogen oxides, and volatile organic compounds[176]. - The company is focusing on improving its emission control technologies to meet environmental regulations[175]. - The company has plans for further investment in pollution control measures to enhance compliance with national standards[175]. Governance and Management - The company has established a governance structure that includes a general meeting of shareholders, a board of directors, a supervisory board, and a management team, ensuring clear responsibilities and coordination among these entities[131]. - The total remuneration for all directors, supervisors, and senior management during the reporting period amounted to 7.5159 million yuan[143]. - The company has not engaged in any business activities that would compromise its independence from its controlling shareholders[131]. - The company is committed to continuous improvement of its governance practices in line with legal and regulatory requirements[131]. Market Position and Strategy - The company holds the largest domestic production capacity for isopropylamine and has been recognized as a champion product by the Ministry of Industry and Information Technology[45]. - The company benefits from significant cost advantages due to large-scale production and favorable procurement agreements for raw materials like acetone, enhancing its market competitiveness[46]. - The company is committed to becoming a leading global supplier of specialty chemicals through continuous technological innovation[114]. - The overall market outlook for the fine chemical industry remains positive, driven by demand for high-quality and environmentally friendly products[82].

Investment Rating - The investment rating for the company is "Buy" (maintained) [5] Core Views - The company's performance in 2024 was under pressure due to declining profitability in the organic solvent segment, but there is optimism for future growth in the fragrance and lithium resource businesses [3][4] - The company achieved a revenue of 2.966 billion yuan in 2024, a year-on-year increase of 14.22%, while the net profit attributable to shareholders was 227 million yuan, a decrease of 10.18% [2][3] - The company has established a strong position in the synthetic fragrance market and is expanding its production capacity in both Ningxia and Jiangsu, which is expected to enhance its competitive edge [4][5] Financial Summary - In 2024, the company reported a revenue of 29.66 billion yuan, with a net profit of 2.27 billion yuan, and a return on equity of 10.19% [2][3] - For Q1 2025, the company achieved a revenue of 7.65 billion yuan, a year-on-year increase of 2.81%, and a net profit of 0.72 billion yuan, a decrease of 5.98% [2][3] - The projected net profits for 2025, 2026, and 2027 are 3.07 billion yuan, 3.75 billion yuan, and 4.52 billion yuan respectively, with corresponding EPS of 1.59, 1.94, and 2.35 yuan [10][12]